The sales of systemic hormonal preparations (excluding sex hormones and insulins) in Japan are projected to remain constant from 2024 to 2028, accounting for 2.9% of the total sales annually. Given the consistency in forecasted values, no year-on-year variations or significant trends are observable from the provided data. This stability suggests that the market for these products may be saturated or witnessing a plateau in demand.
Future trends to watch for include potential impacts from new regulatory policies, emerging healthcare innovations, and shifts in demographics such as aging populations or changes in disease prevalence, which could influence market dynamics and demand for hormonal treatments.
